Cancer evolves and adapts at an alarming rate, making it difficult to study or treat if you don’t have precise insights into the behavior of every cancerous cell.
For researchers, this means the need to examine the diversity of changes in DNA, which include both single nucleotide variants (SNVs) that occur at a specific position in the genome, and copy number variations (CNVs), where larger portions of the genome can be amplified or deleted. Both of these variants are key to cancer and other genetic disease research.
But the ability to analyze CNVs has never before available for single-cell DNA analysis, limiting insight into all of the genomic variations that drive disease — until now.
Today, we’re excited to announce the launch of Copy Number Analysis for our Tapestri Platform, pioneering the extension of CNV capabilities to Tapestri Single-Cell DNA Panels. Never before available on the market, CNV analysis is the remaining technical capability necessary to offer our customers a comprehensive, single-cell DNA solution.
The Tapestri Platform is already the market leader in detecting and tracking mutations to characterize clonal heterogeneity, and with this launch, it now stands as the first and only commercial platform with insight to co-detect both SNVs and CNVs from the same single-cells.
With the Tapestri Platform, researchers can now use a single solution to measure nearly every type of DNA change in every diseased cell. That means major cost savings and improved workflow for sample preparation while enabling even deeper insight into patterns of tumor evolution, therapy response, and resistance.
Cancer is an inherently complicated disease, but we can help simplify the study of it. Through these tools, we’re empowered with a depth of understanding to take us one step closer to a cure.